Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer

Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer

Abstract Endoxifen, a secondary tamoxifen metabolite, is a potent antiestrogen exhibiting estrogen receptor alpha (ERα) binding at nanomolar concentrations. Phase I/II clinical trials identified clinical activity of Z-endoxifen (ENDX), in endocrine-refractory metastatic breast cancer as well as ERα+...

Full description

Bibliographic Details
Main Authors: Swaathi Jayaraman, Xinyan Wu, Krishna R. Kalari, Xiaojia Tang, Mary J. Kuffel, Elizabeth S. Bruinsma, Shahrzad Jalali, Kevin L. Peterson, Cristina Correia, Rachel A. Kudgus, Scott H. Kaufmann, Santosh Renuse, James N. Ingle, Joel M. Reid, Matthew M. Ames, Alan P. Fields, Matthew J. Schellenberg, John R. Hawse, Akhilesh Pandey, Matthew P. Goetz
Format: Article
Language:English
Published: Nature Portfolio 2023-12-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-023-00606-2

Internet

https://doi.org/10.1038/s41523-023-00606-2

Similar Items